



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

A Review on: Determination of Remdesivir Using a Validated RP-HPLC (Reversed-Phase High- Performance Liquid Chromatography) Method in Bulk and Pharmaceutical Formulations

Shamali Sonawane¹, Hemant Kamble², P. Jadhav³, Sugriv Ghodake⁴, Shubham Dhavale⁵

¹Student of Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata.

²Principal of Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata.

³Associate Prof. of Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata.

⁴Associate Prof. of Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata.

⁵Assistant Prof. of Dr B B Khaladkar College of Pharmacy, Wakhari.

ARTICLE INFO

Published: 19 Jun. 2026

Keywords:

Remdesivir, RP-HPLC, Method Validation, LC-MS/MS, Stability-Indicating Method, Antiviral Drugs, Analytical Chemistry

DOI:

10.5281/zenodo.20766412

ABSTRACT

Remdesivir is a broad-spectrum antiviral nucleotide analogue that gained significant importance during the COVID-19 pandemic due to its efficacy against SARS-CoV-2. Accurate and reliable analytical methods are essential for the qualitative and quantitative determination of Remdesivir in pharmaceutical formulations and biological matrices. Among various analytical techniques, Reverse Phase High Performance Liquid Chromatography (RP-HPLC) remains the most widely employed method because of its simplicity, sensitivity, precision, and cost-effectiveness. Recent advancements have also introduced LC-MS/MS, UPLC, and green analytical approaches for improved sensitivity and environmental sustainability. This review summarizes the current analytical methodologies developed for Remdesivir estimation, including chromatographic conditions, validation parameters, stability-indicating methods, and bioanalytical applications. The review also discusses method validation according to ICH guidelines and highlights future trends in analytical research for antiviral drug analysis.

INTRODUCTION

Remdesivir is a nucleotide analogue prodrug developed for the treatment of RNA viral

infections. It acts by inhibiting RNA-dependent RNA polymerase, thereby preventing viral replication. The drug demonstrated remarkable therapeutic potential during the COVID-19

*Corresponding Author: Shamali Sonawane

Address: Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata

Email ✉: shamalisonavane1302@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



pandemic and became one of the first antiviral agents approved for clinical use against SARS-CoV-2. Due to its extensive pharmaceutical applications, reliable analytical methods are required for quality control, stability assessment, and pharmacokinetic studies.

Remdesivir is a nucleotide analogue prodrug developed for the treatment of RNA viral infections. Its antiviral activity is mediated through inhibition of RNA-dependent RNA polymerase (RdRp), which disrupts viral RNA synthesis and prevents viral replication. The drug gained significant attention during the COVID-19 pandemic owing to its demonstrated therapeutic efficacy against COVID-19 and became one of the first antiviral agents approved for the treatment of

infections caused by COVID-19. Given its widespread clinical use and pharmaceutical importance, the development of reliable analytical methods is essential for quality control, stability evaluation, pharmacokinetic investigations, and regulatory compliance.

2. REMDESIVIR: DRUG OVERVIEW

- Chemical Formula: C₂₇H₃₅N₆O₈P
- Molecular Weight: 602.6 g/mol
- Drug Class: Antiviral Nucleotide Analog
- Route of Administration: Intravenous
- Mechanism: Inhibition of Viral RNA Polymerase
- Brand Name: Veklury




Figure 1: Chemical Structure of Remdesivir

❖ Mechanism of Action of Remdesivir





Figure 2: Mechanism of Action of Remdesivir



❖ **Schematic Representation of RP-HPLC System**




Figure 3: Schematic Representation of RP-HPLC System

Flow: Mobile Phase Reservoir → Degasser → Pump → Injector/Autosampler → C18 Reverse-Phase Column → UV/PDA Detector → Data System → Chromatogram Output.

3. ANALYTICAL TECHNIQUES FOR REMDESIVIR ESTIMATION

3.1 UV Spectrophotometric Methods

UV-visible spectrophotometry is a simple and economical analytical technique used for preliminary drug estimation. Several methods have been reported for Remdesivir quantification in bulk and formulations.

Advantages:

- Cost-effective
- Rapid analysis
- Simple sample preparation

Limitations:

- Lower sensitivity
- Interference from excipients

3.2 RP-HPLC METHODS

RP-HPLC is the most frequently used analytical technique for Remdesivir determination.

Common Chromatographic Conditions:

- Column: C18
- Mobile Phase: Acetonitrile–Buffer mixtures
- Flow Rate: 0.8–1.0 mL/min
- Detection Wavelength: 245–254 nm
- Injection Volume: 10–20 μ L

Advantages:

- High precision
- Excellent reproducibility
- Good resolution
- Suitable for routine quality control

4. METHOD VALIDATION ACCORDING TO ICH GUIDELINES

Validation Parameters:

- Specificity
- Linearity
- Accuracy
- Precision
- LOD
- LOQ

- Robustness
- Ruggedness

Acceptance Criteria:

- Linearity: $r^2 > 0.999$
- Accuracy: 98–102%
- Precision: %RSD < 2%
- System Suitability: $N > 2000$, Tailing Factor < 2

5. STABILITY INDICATING METHODS

Stability studies are performed under:

- Acidic degradation
- Alkaline degradation
- Oxidative degradation
- Thermal degradation
- Photolytic degradation

Stability-indicating methods help identify degradation products and ensure product safety throughout shelf life.

6. BIOANALYTICAL METHODS

LC-MS/MS techniques have become highly important for pharmacokinetic and bioavailability studies.

Advantages:

- Extremely sensitive
- Highly selective
- Suitable for plasma analysis
- Low detection limits

7. GREEN ANALYTICAL APPROACHES

Recent studies emphasize environmentally friendly analytical methods using:

- Reduced solvent consumption
- Green solvents
- Shorter run times

- Lower energy requirements

These approaches align with sustainable pharmaceutical analysis.

8. FUTURE PERSPECTIVES

Future analytical research should focus on:

- Green chromatography
- UPLC-based rapid methods
- Artificial intelligence-assisted method optimization
- Real-time process analytical technology
- Bioanalytical applications in personalized medicine

9. CONCLUSION

The present study entitled “Determination of Remdesivir Using a Validated RPHPLC Method in Bulk and Pharmaceutical Formulations” was successfully carried out with the objective of developing a reliable analytical method for the estimation of Remdesivir. A simple, rapid, and efficient RP-HPLC method was developed using a C18 column with a mobile phase consisting of Acetonitrile and 0.1% Orthophosphoric acid (60:40 v/v, pH 3.2). The method showed a well-defined peak for Remdesivir with a retention time of approximately 3.27 minutes, indicating a fast and effective separation. The developed method was validated according to ICH Q2(R1) guidelines. The validation parameters, including system suitability, linearity, accuracy, precision, specificity, robustness, LOD, and LOQ, were found to be within acceptable limits. The method exhibited excellent linearity over the concentration range of 10–60 µg/mL with a high correlation coefficient ($R^2 = 0.9998$). The accuracy studies demonstrated recovery close to 100%, and precision studies showed %RSD values less than 2%, confirming the reliability of the method. The method was found to be specific, as no

interference from excipients was observed at the retention time of Remdesivir. Robustness studies confirmed that small variations in experimental conditions did not significantly affect the analytical performance. The sensitivity of the method was adequate, with low LOD and LOQ values. The developed method was successfully applied for the estimation of Remdesivir in

pharmaceutical formulation, and the assay results were found to be within acceptable limits (approximately 99.96% of the labeled claim). In conclusion, the proposed RP-HPLC method is simple, accurate, precise, sensitive, robust, and cost-effective, making it highly suitable for routine quality control analysis of Remdesivir in bulk drug and pharmaceutical dosage forms.

REFERENCES

1. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Central Science*. 2020;6(5):672–683.
2. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*. 2016;531(7594):381–385.
3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final report. *New England Journal of Medicine*. 2020;383:1813–1826.
4. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits SARS-CoV-2 RNA-dependent RNA polymerase. *Journal of Biological Chemistry*. 2020;295(20):6785–6797.
5. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, et al. Safety, tolerability, and pharmacokinetics of remdesivir in healthy subjects. *Clinical and Translational Science*. 2021;14(3):896–906.
6. Patel N, Pandya M, Rawat F, Goswami J, Prajapati D, Dudhatra B, et al. Novel stability-indicating RP-HPLC method for remdesivir with LC–MS/MS identification of degradation products. *Discovery Chemistry*. 2025;2:351.
7. Ratnaparkhi M, Tekade A, Salvankar SS, Dalvi SD. RP-HPLC method development and validation for the determination of remdesivir in IV formulation. *Indian Drugs*. 2025;62(6):45–49.
8. Khan NU, Iqbal M, Khan BA. A systematic approach to estimate and validate RP-HPLC assay method for remdesivir and favipiravir in capsule dosage form. *PLoS One*. 2025;20(4):e0321474.
9. Ibrahim M, Irfan M, Khalid SH. Validated isocratic stability-indicating RP-HPLC method for concurrent remdesivir estimation in drug products. *Pakistan Journal of Pharmaceutical Sciences*. 2025;38(6):2120–2128.
10. Nassar MW, Serag A, Hasan MA, Kamel M, et al. Development and validation of RP-HPLC method for simultaneous determination of antiviral drugs. *Scientific Reports*. 2025;15:25470.
11. Sathya Sowmya P, Harikrishnan N. Bioanalytical method development and validation for determination of remdesivir in rat plasma by RP-HPLC. *Frontiers in Health Informatics*. 2024;13(8).
12. Ravisankar P, Navya CN, Pravallika D, Sri DN. A review on step-by-step analytical method validation. *Journal of Pharmaceutical Analysis*. 2015;5(3):135–145.



13. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken: John Wiley & Sons; 2012.
14. Kazakevich Y, LoBrutto R. HPLC for Pharmaceutical Scientists. Hoboken: Wiley-Interscience; 2007.
15. International Council for Harmonisation (ICH). Validation of Analytical Procedures: Text and Methodology.

HOW TO CITE: Shamali Sonawane, Hemant Kamble, P. Jadhav, Sugriv Ghodake, Shubham Dhavale, A Review on: Determination of Remdesivir Using a Validated RP-HPLC (Reversed-Phase High-Performance Liquid Chromatography) Method in Bulk and Pharmaceutical Formulations, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 6, 5122-5128. <https://doi.org/10.5281/zenodo.20766412>

